Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCRinhibitor setting: aUKwide analysis

Authors:

Abstract
Summary: Venetoclax is aBCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/RCLLpatients who received venetoclax pre‐National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1–15). 48% hadTP53disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3‐kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no priorBTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR23%) inBTKi‐exposed patients, 92% (CR38%) in Pi3Ki‐exposed patients and 80% (CR20%) in both (P = 0·59). With a median follow‐up of 15·6 months, 1‐year progression‐free survival was 65·0% and 1‐year overall survival was 75·1%. Dose reduction or temporary interruption did not result in an inferior progression‐free or discontinuation‐free survival. Risk of progression or death after stopping a priorBCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2·01P = 0·05). Venetoclax is active and well tolerated in R/RCLLpost ≥1BCRi. Reason(s) for stoppingBCRi influences venetoclax outcomes.
Funding Information
  • Oxford NIHR Biomedical Research Centre

This publication has 15 references indexed in Scilit: